QTTB Stock Forecast: Q32 Bio, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Q32 Bio, Inc. is $38. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 61 of 100 as at 21 Nov 2026 — in the upper half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Q32 Bio, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Quality (87): The business earns solid, repeatable profits on what it owns.
Accruals (11): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
QTTB stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on QTTB, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 12 Oct 2026 | Leerink Partners | Initiates | Outperform | $40 |
| 28 Sept 2026 | Jefferies | Initiates | Buy | $29 |
| 24 Aug 2026 | Morgan Stanley | Initiates | Overweight | $34 |
| 28 July 2026 | HC Wainwright & Co. | Maintains | Buy | $13 → $36 |
| 13 July 2026 | Oppenheimer | Maintains | Outperform | $20 → $40 |
| 13 July 2026 | Wells Fargo | Upgrade | Overweight | $66 |
| 22 May 2026 | Mizuho | Initiates | Outperform | $14 |
| 18 May 2026 | Cantor Fitzgerald | Initiates | Overweight | — |
| 5 May 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 25 Feb 2026 | HC Wainwright & Co. | Initiates | Buy | — |
| 12 Mar 2025 | Wells Fargo | Maintains | Equal-Weight | — |
| 11 Feb 2025 | BMO Capital | Downgrade | Market Perform | — |
| 11 Feb 2025 | Piper Sandler | Downgrade | Neutral | — |
| 12 Dec 2024 | BMO Capital | Maintains | Outperform | — |
| 12 Dec 2024 | Guggenheim | Downgrade | Neutral | — |
| 11 Dec 2024 | Leerink Partners | Downgrade | Market Perform | — |
| 11 Dec 2024 | Oppenheimer | Maintains | Outperform | — |
| 11 Dec 2024 | Piper Sandler | Maintains | Overweight | — |
| 11 Dec 2024 | Raymond James | Downgrade | Outperform | — |
| 11 Dec 2024 | Wells Fargo | Downgrade | Equal-Weight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for QTTB.
This page is one stock. Monday covers all of them.
QTTB appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
QTTB vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Q32 Bio, Inc. returned +332.1% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
QTTB analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 2.3×
- Price / sales
- 4.6×
- Price / book
- 0.9×
- EV / EBITDA
- —
Cheaper than 90% of US stocks
Cheaper than 23% of US stocks
Cheaper than 75% of US stocks
- Revenue growth (YoY)
- −100.0%
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- 34.2%
- Net margin
- 60.0%
Higher than 1% of US stocks
Higher than 90% of US stocks
Higher than 97% of US stocks
- Return on equity
- 24.0%
- Return on assets
- 6.5%
- Dividend yield
- —
Higher than 84% of US stocks
Higher than 82% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Q32 Bio, Inc. has a market value of $249.6M.
Revenue in the twelve months to 30 June 2026: $53.7M.
Net income over the same four quarters: $33.8M, a 62.9% net margin.
Free cash flow in the twelve months to 30 June 2026: −$19.8M.
Trailing P/E: 2.3×.
Q32 Bio, Inc. employs 25 people — $2.1M of revenue per employee.
Data provided by Twelve Data
QTTB and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at QTTB’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Q32 Bio, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about QTTB
What is the QTTB stock price forecast for 2026-2027?
The median 12-month analyst price target for Q32 Bio, Inc. is $38, with estimates ranging from $29 to $59. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is QTTB stock a buy right now?
Of the 7 analysts covering Q32 Bio, Inc., 7 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Q32 Bio, Inc. 61 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank QTTB?
As at 21 Nov 2026, Q32 Bio, Inc. ranks 61 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Quality (87 of 100).
Will QTTB stock go up?
No one can know that. What the data says: the median 12-month target from 7 analysts is $38, and Ticker Nerd's factor model ranks Q32 Bio, Inc. 61 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the QTTB stock forecast for 2030?
No analyst covering Q32 Bio, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for QTTB are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $29 to $59 over the next 12 months.
How has QTTB stock performed over the past year?
Q32 Bio, Inc. returned +332.1% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Q32 Bio, Inc. do?
Q32 Bio Inc. is a clinical-stage biotechnology company focused on developing biologic therapies for autoimmune and inflammatory diseases driven by immune system dysfunction. The company’s current programs center on restoring healthy immune balance through targeted modulation of the adaptive and innate immune systems, with a lead emphasis on treatments for alopecia areata and other immune-mediated conditions.
About Q32 Bio, Inc.
Q32 Bio Inc. is a clinical-stage biotechnology company focused on developing biologic therapies for autoimmune and inflammatory diseases driven by immune system dysfunction. The company’s current programs center on restoring healthy immune balance through targeted modulation of the adaptive and innate immune systems, with a lead emphasis on treatments for alopecia areata and other immune-mediated conditions. Q32 Bio’s pipeline includes bempikibart, an antibody-based candidate designed to regulate immune signaling in dermatology and related autoimmune settings, as well as research efforts in complement-pathway biology for tissue-targeted immune control. The company’s work is positioned within the broader biopharmaceutical sector, where precision immunology and biologics play an important role in addressing chronic diseases with limited treatment options. Based in Waltham, Massachusetts, Q32 Bio continues to operate as a research-focused company advancing specialized therapies from clinical development programs.
CEO Ms. Jodie Pope Morrison · 25 employees · United States · https://www.q32bio.com